Given the lack of long-term data, we are often left with more questions than answers about determining the appropriate management of these patients. Caring for women with estrogen receptor–positive tumors and BRCA mutations can add additional complexity. Women with hormone receptor–positive tumors face years of estrogen deprivation and/or endocrine therapy that is contraindicated during pregnancy. BRCA mutation carriers may also consider risk-reducing surgeries to decrease the risk of second breast cancers or to prevent ovarian cancers, thus further limiting fertility potential.
Fertility Preservation in Women With Breast Cancer: Challenges and Opportunities
